Two logos side by side with Critical Legal Content in a red square on the left and HB Litigation in blue on the right

Mass injuries or damage caused by chemicals, defective products, drugs, medical devices, or any substance or environmental factor that cause harm to a group of individuals. Relates to Environmental.

Organizational Values & Business Risks: Properly Balancing Stakeholder Concerns

August 6th, 2020|Categories: CLE OnDemand, Complex Business Litigation, Corporate Compliance, Employment, HB Risk Notes, Mass Torts, News|Tags: , , , |

Accommodations. Appropriate accommodation for high-risk employees or employees with family members who are at a heightened risk. Mitigation. Attention to means of mitigating transmission and infection. Tracing. Contact tracing and management of data collected, including health data, as well as responses to employees who refuse to report. Patient Sensitivity. Duty to avoid discrimination and stigmatization. Preparedness. Developing plans to address possibility of re-occurrence in the fall and managing possible outbreaks in company’s offices. On-demand on the Thomson Reuters West LegalEdcenter as part of the HB catalog. Organizational Values & Coronavirus Business Risks: Properly Balancing Stakeholder Concerns Produced for Emory University Center for Ethics by HB Litigation Conferences The current pandemic confronts businesses, nonprofit organizations, governments, and the legal profession with innumerable ethical challenges.  Management issues and liability concerns, stakeholder demands and legal duties become even more complex in an environment of uncertainty and one where the consequences could result in serious illness or even death.  This program seeks to engage the participants in thinking through these challenges and developing processes of ethical response to them.  Managers must acknowledge and address the framework of fear associated with the pandemic, ranging from fear of contagion and death to fears of unemployment, childcare, and the duties of home-schooling.  Additionally, as the economy reopens there must be [...]

Read More

The Dark Net: Anonymity, Infrastructure, and the Future

July 10th, 2020|Categories: Corporate Compliance, HB Risk Notes, Mass Torts, News, Technology Law|Tags: , , , , |

Register Webinar Info Wednesday, Aug. 5, 2020 United States 8am PT | 10am CT | 11am ET United Kingdom 4pm BST Get CLE or CPE, a complete set of materials, and answers to your questions! Email us your: Speaker questions CLE questions Topics Covered Physical and Logical Topology and Method of Data Transmission Using the Dark Net for Threat Hunting Hacking Groups and Malicious Hackers   The Future of The Dark Net and Anonymity The Dark Net: Anonymity, Infrastructure, and the Future Is the Dark Web Getting Darker?  Wed., Aug. 5, 2020 | Produced for Access Data by HB Litigation Conferences The web, however singular it may seem from behind an everyday user’s computer or smartphone screen, comprises three distinctive parts: the public net (or web), the deep net, and the dark net. Though the dark net contains some innocuous content and is used for legitimate purposes, it also operates as a platform for illegal marketplaces. These offer almost anything a criminal or cybercriminal might want to buy or sell like malware, exploits, hackers-for-hire, information lifted from data breaches, censored content, and goods like drugs, guns, and other contraband. Observers report that the dark web is getting darker, meaning hardcore criminals make up a greater percentage of its user base. Exploits and [...]

Read More

Monsanto, Bayer Paying Billions for PCB Cleanups

July 3rd, 2020|Categories: Class Actions, Complex Business Litigation, HB Tort Notes, Mass Torts|Tags: , |

Read Baltimore Sun environmental writer Scott Dance's June 24, 2020, article titled, "A $550M national class-action settlement includes money for cleanup of PCBs in Baltimore waterways." He offers the Maryland angle on the $550 million class action settlement between Monsanto and 13 government agencies across the U.S., just part of a much larger agreement. "The settlement was one of several that Monsanto’s owner, German pharmaceutical company Bayer, announced Wednesday. Bayer said it’s paying up to $10.9 billion to settle current and potential future litigation over Monsanto’s weedkiller Roundup, which has faced numerous lawsuits over claims it causes cancer, and $1.22 billion to settle two further cases, including the class action focused on PCBs." Dance writes that the terms of this settlement are off to Judge Fernando M. Olquin of the Central District of California for his review. Judge Olquin was one of the presenters on multiple panels at the Class Action Law Forum presented by Western Alliance Bank and produced by my team at HB. Kenneth R. Feinberg, also a presenter, is the court-appointed special master in the case. The Baltimore Sun piece was one of many that gave the local perspective on this nationwide litigation and settlement in progress, like this one from the San Francisco Chronicle, with a Seattle dateline, and this one from the Washington State Wire quoting [...]

Read More

The Intersection of Antitrust & Privacy | A MoginRubin Webinar | 10.31.2019

September 14th, 2019|Categories: CLE OnDemand, Complex Business Litigation, HB Risk Notes, Mass Torts, Technology Law|Tags: , , , , |

[two-fifths-first] Recorded: Oct. 31, 2019 Duration: 100 minutes Presented by:  MoginRubin LLP Produced by: HB Litigation Conferences The Panel Moderator Daniel J.  Mogin | Managing Partner, MoginRubin LLP Speakers Jennifer M. Oliver, CIPP/US | Partner, MoginRubin LLP Thomas N. Dahdouh | Director, Western Region, Federal Trade Commission Franklin M. Rubinstein | Partner, Wilson Sonsini Goodrich & Rosati Randi W. Singer, CIPP/US, CIPT | Partner, Weil, Gotshal & Manges Contributor Dina Srinivasan | Independent Researcher & Author of The Antitrust Case Against Facebook Dina was unable to present but we thank her for her content contributions.  What you will get: At least 1 hour of CLE credit. Answers to your questions via email. The opportunity to share with others on your team. The complete Powerpoint. The Antitrust Case Against Facebook Dina Srinivasan's statement to the House Committee on the Judiciary, Subcommittee on Antitrust, Commercial, and Administrative Law The Chicago Booth School Stigler Center Committee on Digital Platforms Final Report Write to us at CLE@LitigationConferences.com to: Ask about CLE Request the materials Send a question for the speakers [/two-fifths-first][three-fifths] Market Behavior and Data-Driven Market Power Highly publicized cases and investigations in the U.S. and Europe of big technology, e-commerce, and social media companies demonstrate how anti-competition laws are being used to scrutinize and challenge not only how these corporations conduct themselves in the [...]

Read More

PTSD in Multi-Plaintiff and Mass Tort Cases | Webinar OnDemand

July 19th, 2019|Categories: Class Actions, Complex Business Litigation, Employment, HB Risk Notes, Mass Torts|Tags: , , , , |

[one-fourth-first]   Price: $47 When: On-demand Where: Your computer or mobile device CLE: 1 hour Speakers Mark I. Levy MD, DLFAPA Medical Director Forensic Psychiatric Associates Medical Corporation Associate Clinical Professor, Psychiatry University of California, San Francisco, School of Medicine 415.388.8040 mlevy@fpamed.com  Sarah A. Hall, PhD. Psychologist for Forensic & Neuropsychological Assessments Forensic Psychiatric Associates Medical Corporation shall@fpamed.com  [/one-fourth-first][three-fourths] What tort attorneys need to know about PTSD claims. Mass tort claims arise most frequently in man-made and natural disaster catastrophe litigation as well as personal injury, employment, product liability and toxic tort litigation. Frequently, these lawsuits include either primary or secondary allegations of emotional distress. PTSD is one of the most common emotional distress claims alleged within mass tort litigation, as well as allegations of depression and emotional stress (anxiety).  Join an experienced psychiatrist and psychologist who will cover the following topics relevant to the forensic psychiatric assessment of emotional damages within mass tort and complex litigation:  + Introduction: Defining PTSD. What it is and what it is not. + The methodological approach to assessing allegations of emotional distress in mass tort & complex litigation. + The importance and the methodology of psychological testing as part of the assessment of emotional distress claims in mass tort litigation. + Claimant population screening. Using psychological test instruments to differentiate claimants who [...]

Read More

CNN — Jury returns $2 billion verdict against Monsanto for couple with cancer — the biggest so far

June 5th, 2019|Categories: Class Actions, Environmental Torts, HB Tort Notes, Mass Torts|Tags: , |

[one-half-first] [/one-half-first] [one-half] A California jury returned a $2.055 billion verdict against Monsanto and their popular weed killer, Roundup. “The verdict in Oakland includes more than $55 million in compensatory damage and $2 billion in punitive damages.” The septuagenarian plaintiffs, represented by attorney Michael Miller of The Miller Firm, were a California couple that said long-term exposure to Roundup caused both of them to be diagnosed with non-Hodgkin lymphoma, a cancer that usually cannot be traced back to a source according to the American Cancer Society. The particular carcinogen in Roundup is glyphosate, which the EPA has stated was not a carcinogen in a 2015 assessment, which contradicts WHO’s statement that glyphosate is “probably carcinogenic to humans”. While a Monsanto spokesperson previously denied any manipulation, a jury found that a series of texts and emails between Monsanto and the EPA that proved Monsanto culpable of manipulating science. [/one-half] Read the complete post by Michael Nedelman on CNN.com here!

Read More

The Wrong-Headedness of Hindsight Standards — Michelle Yeary | Drug & Device Law Blog

May 27th, 2019|Categories: Complex Business Litigation, HB Risk Notes, Mass Torts|Tags: , , , |

Dechert LLP attorney Michelle Yeary cautions against applying perfect hindsight to drug liability. "We all know hindsight is 20/20.  And, it’s easy.  There are dozens of television and radio programs that thrive on Monday morning quarterbacking.  There’s no risk in saying the coach should have called for a pass when you already know the run didn’t work.  It’s also dangerous because it’s easy.  People are often too quick to point out that you should have taken path B after everyone learns path A is full of potholes.  Pointing it out is one thing, holding you liable for it is another." Yeary takes a look at what happened in Holley v. Gilead Science, Inc., 2019 WL 2077845 (N.D. Cal. May 10, 2019). The case involves two of the main active ingredients in AIDS drugs: TDF and TAF. The plaintiff alleges that the defendant should be responsible for allegedly knowingly using TDF over TAF (allegedly a safer alternative). TDF was FDA approved first and TAF second.  Unfortunately, Yeary wrote, hindsight "can be used to demand perfection," allowing  plaintiffs to "proceed on what is essentially a stop-selling theory," that first-generation drugs should not be submitted to the FDA because, in hindsight, "later approved treatments were safer." That's what happened in Holley, she said. Read the complete post by Michelle Yeary on the Drug and [...]

Read More

J&J Hit with $120 Million Verdict at Mesh Trial

May 13th, 2019|Categories: Complex Business Litigation, HB Risk Notes, Mass Torts|Tags: , , |

A Philadelphia jury returned a $120 million verdict against Johnson & Johnson after finding that a negligently designed pelvic mesh implant caused chronic pain and suffering, which left plaintiff Susan McFarland incontinent and unable to have sex for the last 10 years. McFarland alleged the implant she received in 2008 caused the product to saw through the soft tissue in her pelvis and become exposed in her vagina. She had to undergo a second surgery to remove a portion of the implant (Susan McFarland,et al. v. Ethicon Inc., et al., No. 130701577, Phila. Comm. Pls. Ct.). This is the second of two trials. The jury in the first trial was deadlocked, unable to agree on the extent of negligence of the design of the Ethicon product. Tracie Palmer, McFarland’s attorney, added in the second trial that the vaginal mesh was on market prior to clinical studies determining its safety and efficacy.  Defense attorney Adam Spicer maintained that the chronic pain McFarland experienced could be due to other causes, including her age. He said the product had been used for years prior.  McFarland’s case is one of more than 100,000 cases brought together in the MDL, down from nearly 105,000 cases against seven manufacturers.  The MDL will be closing and there will be two more waves of trial, with next wave comprising [...]

Read More

Philadelphia Jury Hits J&J with $120M Award in Mesh Injury Case — Law360

April 25th, 2019|Categories: Complex Business Litigation, HB Tort Notes, Mass Torts|Tags: , , , |

[one-half-first][/one-half-first] [one-half] "Jurors credited claims from Susan McFarland that the negligent design of a mesh implant she received in 2008 caused the product to saw through the soft tissue in her pelvis and become exposed in her vagina. She was eventually forced to undergo a second surgery to remove a portion of the implant. "The pain she’s been left with as a result of the complications, she says, has prevented her from having sex with her husband for the last 10 years. "This is the second time jurors have been asked to determine whether McFarland and her husband should be awarded damages for injuries she attributes to alleged defects in a so-called TVT-O implant she received to treat urinary stress incontinence." Read the complete article on Law360 here. [/one-half]

Read More

Top Class Actions: Vaccine Litigation Case Roundup

April 19th, 2019|Categories: Class Actions, HB Risk Notes, Mass Torts|Tags: , , |

[one-half-first][/one-half-first] [one-half]There have been numerous lawsuits filed alleging injuries caused by the shingles vaccine Zostavax. Cases have stated they were not warned of the adverse side effects of the vaccine alleging it caused the diseases it is meant to prevent, among other things. Here is what the CDC says to consumers: “Your risk of shingles and postherpetic neuralgia (PHN) increases as you get older. CDC recommends that people 60 years old and older get shingles vaccine (Zostavax®) to prevent shingles and PHN. Shingrix (recombinant zoster vaccine) is the preferred vaccine, over Zostavax® (zoster vaccine live), a shingles vaccine in use since 2006. Zostavax may still be used to prevent shingles in healthy adults 60 years and older. For example, you could use Zostavax if a person is allergic to Shingrix, prefers Zostavax, or requests immediate vaccination and Shingrix is unavailable. Zostavax (zoster vaccine live) was licensed by the FDA in 2006. This vaccine reduces the risk of developing shingles by 51% and PHN by 67%. It is given in one dose as a shot, and can be given in a doctor’s office or pharmacy.“ Read more: https://www.cdc.gov/vaccines/vpd/shingles/public/zostavax/index.html The vaccine is produced by Merck & Co.  Their product information can be found here: https://www.merckvaccines.com/Products/Zostavax Here is a roundup of the cases filed. [/one-half] 1.Husband and Wife File Zostavax Shingles Vaccine Lawsuit  "A North Carolina husband and [...]

Read More

The Need for Real MDL Rules Will Only Grow More Acute — Drug and Device Law Blog

April 16th, 2019|Categories: Complex Business Litigation, HB Tort Notes, Mass Torts|Tags: , , |

By Bexis  [one-half-first].[/one-half-first] [one-half]"In the ensuing procedural gamesmanship, plaintiffs are in the process of losing one of the main ways they gamed the system to keep diverse cases in state court – the so-called 'forum defendant rule' whereby even a diverse action could be kept in state court by the presence of defendant domiciled in the plaintiff’s chosen forum. The forum defendant rule applies only to parties 'properly joined and served,' and technologically-savvy defendants have discovered that, by monitoring electronic dockets, they can remove diverse cases faster than plaintiffs can serve forum defendants. We call this 'pre-service,' 'snap,' or 'wrinkle' removal, and we’ve chronicled (and advocated) its rise since 2007." Read the complete post by Bexis on Drug and Device Law Blog here. [/one-half] This is an excellent blog. One of my favorites. It's unapologetically defense-oriented, of course. A phrase like "gamed the system" is practically an invitation for rebuttal! So if you would like to respond, rebut, or rebuke, please write to us at Editor@LitigationConferences.com. --Tom Hagy, HB

Read More

A Generic Drug Failure to Warn Claim? –Michelle Hart Yeary

April 14th, 2019|Categories: Complex Business Litigation, HB Tort Notes, Mass Torts|Tags: , , , |

[one-half-first][/one-half-first] [one-half] "Rather than focusing on what plaintiff’s off-label marketing claim really was – a claim that defendant’s label should have contained different information or warnings about off-label uses – an impliedly preempted claim, the court got distracted trying to fit the case in under Bausch and started talking about parallel violation claims. "The court found that because plaintiff was alleging a violation of federal regulations, his claims “run parallel to [defendant’s] state law duties,” and thus were not preempted. The problem with this is that Mensing is not an express preemption case.  It was an implied preemption case, and the district court had no business applying 'parallel claim' analysis to implied preemption, where a 'parallel claim' exception does not exist.  It makes no difference whether plaintiff’s off-label promotion claim is 'parallel' to federal regulations, defendant could not have offered any different warning so any claim that the warning or information it provided was inadequate is preempted under Mensing.  The court was trying to fit a square peg into a round whole – and the only way that works is to cut off the corners." Read the complete post by Dechert's Michelle Hart Yeary here! [/one-half]

Read More
Go to Top